EW — Edwards Lifesciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Edwards Lifesciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	5,233	4,464	5,010	5,440	6,068
Cost of Revenue
Gross Profit	3,984	3,740	4,032	4,322	4,733
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,542	2,962	3,701	4,006	4,950
Operating Profit	1,690	1,502	1,309	1,434	1,117
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,702	1,520	1,372	1,548	1,273
Provision for Income Taxes
Net Income After Taxes	1,503	1,324	1,220	1,396	1,056
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	1,503	1,522	1,402	4,175	1,074
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,503	1,522	1,402	4,175	1,074
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.41	2.22	2.3	2.41	2.56